<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03352245</url>
  </required_header>
  <id_info>
    <org_study_id>2000022225</org_study_id>
    <secondary_id>1P50CA196530-01</secondary_id>
    <nct_id>NCT03352245</nct_id>
  </id_info>
  <brief_title>Feasibility of an Activity Regimen in Patients With Advanced Stage Lung Cancer</brief_title>
  <official_title>Assessing the Feasibility of a Patient-centered Activity Regimen in Patients With Advanced Stage Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>VA Connecticut Healthcare System</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will evaluate the feasibility of implementing a low-intensity,&#xD;
      patient-centered activity regimen (PCAR) that prioritizes education and communication over a&#xD;
      12-week period in advanced stage lung cancer patients. The primary outcomes will include&#xD;
      number of patients increasing their overall step count over the study period and adherence to&#xD;
      step count recommendations. Secondary outcomes will include quality of life (QoL), dyspnea,&#xD;
      and depression scores before and after the intervention as well as a patient feedback&#xD;
      questionnaire (to guide further interventions). The goals are to increase overall step count&#xD;
      and obtain adherence of &gt;50% of participants. The investigators will also assess whether the&#xD;
      physical activity regimen influences markers of inflammation and glucose control and novel&#xD;
      markers of cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 26, 2018</start_date>
  <completion_date type="Actual">May 24, 2020</completion_date>
  <primary_completion_date type="Actual">May 24, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Step Count</measure>
    <time_frame>baseline to 12 weeks</time_frame>
    <description>Participants will wear a Fitbit wrist band that will record step count.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Weeks Participants Adhered to Step Count Recommendations</measure>
    <time_frame>baseline to 12 weeks.</time_frame>
    <description>Exercise Adherence will be defined as (the number of weeks a subject follows the activity prescription)/(the number of &quot;usable&quot; weeks). A week is considered &quot;usable&quot; if 5/7 days of step counts are available, and days with &lt;200 steps/day are considered not usable.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dyspnea</measure>
    <time_frame>change from pre- to post-intervention (week 12)</time_frame>
    <description>Assessed via self-report using the Modified Medical Research Council. Dyspnea Scale, a single-item scale scored 0-4; higher score indicates worse dyspnea.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression</measure>
    <time_frame>change from pre- to post-intervention (week 12)</time_frame>
    <description>Assessed via self-report using the Patient Health Questionnaire, Depression Module (PHQ-9). a 9-item questionnaire that assesses depressive symptoms over the preceding two weeks. Each item is scored 0-3 (0 = &quot;Not at all&quot;; 1 = &quot;Several days&quot;; 2 = &quot;More than half of days&quot;; 3 = &quot;Nearly every day&quot;). A total score is calculated by taking the sum of questions 1-9, and a higher score indicates worse depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life: Global Health Status</measure>
    <time_frame>change from pre- to post-intervention (week 12)</time_frame>
    <description>Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales:&#xD;
Global health status/Quality of Life (QoL) scale, range 0-100, higher score = better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life: Physical Functioning</measure>
    <time_frame>change from pre- to post-intervention (week 12)</time_frame>
    <description>Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the 5 functional scales measure physical functioning.&#xD;
The range of score is 0-100; higher score = better functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life: Role Functioning</measure>
    <time_frame>change from pre- to post-intervention (week 12)</time_frame>
    <description>Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the 5 functional scales measures role functioning.&#xD;
The range of score is 0-100; higher score = better functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life: Emotional Functioning</measure>
    <time_frame>change from pre- to post-intervention (week 12)</time_frame>
    <description>Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the 5 functional scales measures emotional functioning.&#xD;
The range of score is 0-100; higher score = better functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life: Fatigue</measure>
    <time_frame>change from pre- to post-intervention (week 12)</time_frame>
    <description>Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the symptom scale measures fatigue.&#xD;
The range of score is 0-100; higher score = better functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life: Cognitive Functioning</measure>
    <time_frame>change from pre- to post-intervention (week 12)</time_frame>
    <description>Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the 5 functional scales measures cognitive functioning.&#xD;
The range of score is 0-100; higher score = better functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life: Nausea/Vomiting</measure>
    <time_frame>change from pre- to post-intervention (week 12)</time_frame>
    <description>Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the symptom scale measures nausea and vomiting The range of score is 0-100; higher score = better functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life: Pain</measure>
    <time_frame>change from pre- to post-intervention (week 12)</time_frame>
    <description>Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the symptom scale measures pain.&#xD;
The range of score is 0-100; higher score = better functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life: Social Functioning</measure>
    <time_frame>change from pre- to post-intervention (week 12)</time_frame>
    <description>Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the 5 functional scales measures social functioning.&#xD;
The range of score is 0-100; higher score = better functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life: Dyspnea</measure>
    <time_frame>change from pre- to post-intervention (week 12)</time_frame>
    <description>Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the scales measure dyspnea.&#xD;
The range of score is 0-100; higher score = higher symptoms burden.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life: Insomnia</measure>
    <time_frame>change from pre- to post-intervention (week 12)</time_frame>
    <description>Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the scales measure insomnia.&#xD;
The range of score is 0-100; higher score = better functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life: Appetite Loss</measure>
    <time_frame>change from pre- to post-intervention (week 12)</time_frame>
    <description>Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the scales measure appetite loss The range of score is 0-100; higher score = higher symptoms burden.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life: Constipation</measure>
    <time_frame>change from pre- to post-intervention (week 12)</time_frame>
    <description>Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the scales measure constipation.&#xD;
The range of score is 0-100; higher score = higher symptoms burden.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life: Diarrhea</measure>
    <time_frame>change from pre- to post-intervention (week 12)</time_frame>
    <description>Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the scales measure diarrhea.&#xD;
The range of score is 0-100; higher score = higher symptoms burden.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life: Financial Difficulties</measure>
    <time_frame>change from pre- to post-intervention (week 12)</time_frame>
    <description>Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the scales measure financial difficulties.&#xD;
The range of score is 0-100; higher score = higher symptoms burden.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Moderate Aerobic Exercise</measure>
    <time_frame>baseline to 12 weeks</time_frame>
    <description>The investigators will use the Physical Activity Questionnaire that measures this outcome in minutes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vigorous Aerobic Exercise</measure>
    <time_frame>baseline to 12 weeks</time_frame>
    <description>The investigators will use the Physical Activity Questionnaire that measures this outcome in minutes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in C-reactive Protein (CRP)</measure>
    <time_frame>change from pre- to post-intervention (week 12)</time_frame>
    <description>The investigators will obtain serum CRP, a marker of inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Leptin Level</measure>
    <time_frame>change from pre- to post-intervention (week 12)</time_frame>
    <description>The investigators will obtain serum leptin, a marker of glucose control. .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Insulin Level</measure>
    <time_frame>change from pre- to post-intervention (week 12)</time_frame>
    <description>The investigators will obtain serum insulin level, a measure of glucose control.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Programmed Death - Ligand</measure>
    <time_frame>change from pre- to post-intervention (week 12)</time_frame>
    <description>The investigators will collect soluble PD- L1, a novel cancer marker.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Programmed Cell Death (PD-1)</measure>
    <time_frame>change from pre- to post-intervention (week 12)</time_frame>
    <description>The investigators will collect soluble PD- 1, a novel cancer marker.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Lung Neoplasm Malignant</condition>
  <arm_group>
    <arm_group_label>Intervention Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prescribed Activity designed to improve patient participation and adherence to prescriptions to increase physical activity and will include: (1) an educational session at enrollment, (2) subject communication via tailored electronic messaging, and (3) a wrist-bound device (FitBit Flex 2).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Usual care group will receive standard of care management from their Oncologist.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Prescribed Activity</intervention_name>
    <description>Educational session at enrollment, increase subject communication via tailored electronic messaging, and use of a wrist-bound device (FitBit Flex 2)</description>
    <arm_group_label>Intervention Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologic evidence of advanced non-small cell stage lung cancer (NSCLC)&#xD;
&#xD;
          -  Approval of the treating clinician&#xD;
&#xD;
          -  Adult patients (age &gt;21 years) willing to wear a FitBitÂ® device (FitBit, Inc., San&#xD;
             Francisco, CA)&#xD;
&#xD;
          -  Access to a smartphone, agree to receive twice/daily text messages for 12 weeks&#xD;
             (including any costs), and willingness to download the FitBit application to their&#xD;
             smartphone.&#xD;
&#xD;
          -  Low activity level as judged by a brief physical activity questionnaire (i.e., &lt;150&#xD;
             minutes/week of moderate-intensity exercise, &lt;75 minutes/week of vigorous aerobic&#xD;
             exercise, or an equivalent combination).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Memory impairment (as judged by the treating clinician)&#xD;
&#xD;
          -  Communication impairment (as judged by the treating clinician)&#xD;
&#xD;
          -  Treating clinician's request not to alter physical activity&#xD;
&#xD;
          -  Physical inability to safely walk (as judged by the treating clinician)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brett Bade, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 20, 2017</study_first_submitted>
  <study_first_submitted_qc>November 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2017</study_first_posted>
  <results_first_submitted>April 23, 2021</results_first_submitted>
  <results_first_submitted_qc>May 18, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 21, 2021</results_first_posted>
  <last_update_submitted>May 18, 2021</last_update_submitted>
  <last_update_submitted_qc>May 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 6, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/45/NCT03352245/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Intervention Group</title>
          <description>Prescribed Activity designed to improve patient participation and adherence to prescriptions to increase physical activity and will include: (1) an educational session at enrollment, (2) subject communication via tailored electronic messaging, and (3) a wrist-bound device (FitBit Flex 2).&#xD;
Prescribed Activity: Educational session at enrollment, increase subject communication via tailored electronic messaging, and use of a wrist-bound device (FitBit Flex 2)</description>
        </group>
        <group group_id="P2">
          <title>Control Group</title>
          <description>Usual care group will receive standard of care management from their Oncologist.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intervention Group</title>
          <description>Prescribed Activity designed to improve patient participation and adherence to prescriptions to increase physical activity and will include: (1) an educational session at enrollment, (2) subject communication via tailored electronic messaging, and (3) a wrist-bound device (FitBit Flex 2).&#xD;
Prescribed Activity: Educational session at enrollment, increase subject communication via tailored electronic messaging, and use of a wrist-bound device (FitBit Flex 2)</description>
        </group>
        <group group_id="B2">
          <title>Control Group</title>
          <description>Usual care group will receive standard of care management from their Oncologist.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.55" spread="7.28"/>
                    <measurement group_id="B2" value="63.20" spread="63.50"/>
                    <measurement group_id="B3" value="64.88" spread="8.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Step Count</title>
        <description>Participants will wear a Fitbit wrist band that will record step count.</description>
        <time_frame>baseline to 12 weeks</time_frame>
        <population>This outcome was measured only in the intervention group.</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention Group</title>
            <description>Prescribed Activity designed to improve patient participation and adherence to prescriptions to increase physical activity and will include: (1) an educational session at enrollment, (2) subject communication via tailored electronic messaging, and (3) a wrist-bound device (FitBit Flex 2).&#xD;
Prescribed Activity: Educational session at enrollment, increase subject communication via tailored electronic messaging, and use of a wrist-bound device (FitBit Flex 2)</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Usual care group will receive standard of care management from their Oncologist.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Step Count</title>
          <description>Participants will wear a Fitbit wrist band that will record step count.</description>
          <population>This outcome was measured only in the intervention group.</population>
          <units>Steps</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4707" lower_limit="1,568" upper_limit="12,222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5605" lower_limit="1,079" upper_limit="9,764"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4606" lower_limit="746" upper_limit="10,238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Weeks Participants Adhered to Step Count Recommendations</title>
        <description>Exercise Adherence will be defined as (the number of weeks a subject follows the activity prescription)/(the number of &quot;usable&quot; weeks). A week is considered &quot;usable&quot; if 5/7 days of step counts are available, and days with &lt;200 steps/day are considered not usable.</description>
        <time_frame>baseline to 12 weeks.</time_frame>
        <population>This outcome was measured only in the intervention group. The 19 participants were each followed for 12 weeks. Thus 19 participants were followed for a total of 228 weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention Group</title>
            <description>Prescribed Activity designed to improve patient participation and adherence to prescriptions to increase physical activity and will include: (1) an educational session at enrollment, (2) subject communication via tailored electronic messaging, and (3) a wrist-bound device (FitBit Flex 2).&#xD;
Prescribed Activity: Educational session at enrollment, increase subject communication via tailored electronic messaging, and use of a wrist-bound device (FitBit Flex 2)</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Usual care group will receive standard of care management from their Oncologist.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Weeks Participants Adhered to Step Count Recommendations</title>
          <description>Exercise Adherence will be defined as (the number of weeks a subject follows the activity prescription)/(the number of &quot;usable&quot; weeks). A week is considered &quot;usable&quot; if 5/7 days of step counts are available, and days with &lt;200 steps/day are considered not usable.</description>
          <population>This outcome was measured only in the intervention group. The 19 participants were each followed for 12 weeks. Thus 19 participants were followed for a total of 228 weeks.</population>
          <units>Weeks</units>
          <param>Count of Units</param>
          <units_analyzed>Weeks</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Weeks</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="228"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dyspnea</title>
        <description>Assessed via self-report using the Modified Medical Research Council. Dyspnea Scale, a single-item scale scored 0-4; higher score indicates worse dyspnea.</description>
        <time_frame>change from pre- to post-intervention (week 12)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention Group</title>
            <description>Prescribed Activity designed to improve patient participation and adherence to prescriptions to increase physical activity and will include: (1) an educational session at enrollment, (2) subject communication via tailored electronic messaging, and (3) a wrist-bound device (FitBit Flex 2).&#xD;
Prescribed Activity: Educational session at enrollment, increase subject communication via tailored electronic messaging, and use of a wrist-bound device (FitBit Flex 2)</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Usual care group will receive standard of care management from their Oncologist.</description>
          </group>
        </group_list>
        <measure>
          <title>Dyspnea</title>
          <description>Assessed via self-report using the Modified Medical Research Council. Dyspnea Scale, a single-item scale scored 0-4; higher score indicates worse dyspnea.</description>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.15"/>
                    <measurement group_id="O2" value="-0.07" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.889</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.03</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.20</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Depression</title>
        <description>Assessed via self-report using the Patient Health Questionnaire, Depression Module (PHQ-9). a 9-item questionnaire that assesses depressive symptoms over the preceding two weeks. Each item is scored 0-3 (0 = &quot;Not at all&quot;; 1 = &quot;Several days&quot;; 2 = &quot;More than half of days&quot;; 3 = &quot;Nearly every day&quot;). A total score is calculated by taking the sum of questions 1-9, and a higher score indicates worse depression.</description>
        <time_frame>change from pre- to post-intervention (week 12)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention Group</title>
            <description>Prescribed Activity designed to improve patient participation and adherence to prescriptions to increase physical activity and will include: (1) an educational session at enrollment, (2) subject communication via tailored electronic messaging, and (3) a wrist-bound device (FitBit Flex 2).&#xD;
Prescribed Activity: Educational session at enrollment, increase subject communication via tailored electronic messaging, and use of a wrist-bound device (FitBit Flex 2)</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Usual care group will receive standard of care management from their Oncologist.</description>
          </group>
        </group_list>
        <measure>
          <title>Depression</title>
          <description>Assessed via self-report using the Patient Health Questionnaire, Depression Module (PHQ-9). a 9-item questionnaire that assesses depressive symptoms over the preceding two weeks. Each item is scored 0-3 (0 = &quot;Not at all&quot;; 1 = &quot;Several days&quot;; 2 = &quot;More than half of days&quot;; 3 = &quot;Nearly every day&quot;). A total score is calculated by taking the sum of questions 1-9, and a higher score indicates worse depression.</description>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.83" spread="0.65"/>
                    <measurement group_id="O2" value="0.31" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.20</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.14</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.88</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quality of Life: Global Health Status</title>
        <description>Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales:&#xD;
Global health status/Quality of Life (QoL) scale, range 0-100, higher score = better quality of life.</description>
        <time_frame>change from pre- to post-intervention (week 12)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention Group</title>
            <description>Prescribed Activity designed to improve patient participation and adherence to prescriptions to increase physical activity and will include: (1) an educational session at enrollment, (2) subject communication via tailored electronic messaging, and (3) a wrist-bound device (FitBit Flex 2).&#xD;
Prescribed Activity: Educational session at enrollment, increase subject communication via tailored electronic messaging, and use of a wrist-bound device (FitBit Flex 2)</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Usual care group will receive standard of care management from their Oncologist.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quality of Life: Global Health Status</title>
          <description>Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales:&#xD;
Global health status/Quality of Life (QoL) scale, range 0-100, higher score = better quality of life.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.16" spread="4.11"/>
                    <measurement group_id="O2" value="-4.63" spread="4.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.166</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>7.79</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.51</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quality of Life: Physical Functioning</title>
        <description>Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the 5 functional scales measure physical functioning.&#xD;
The range of score is 0-100; higher score = better functioning.</description>
        <time_frame>change from pre- to post-intervention (week 12)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention Group</title>
            <description>Prescribed Activity designed to improve patient participation and adherence to prescriptions to increase physical activity and will include: (1) an educational session at enrollment, (2) subject communication via tailored electronic messaging, and (3) a wrist-bound device (FitBit Flex 2).&#xD;
Prescribed Activity: Educational session at enrollment, increase subject communication via tailored electronic messaging, and use of a wrist-bound device (FitBit Flex 2)</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Usual care group will receive standard of care management from their Oncologist.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quality of Life: Physical Functioning</title>
          <description>Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the 5 functional scales measure physical functioning.&#xD;
The range of score is 0-100; higher score = better functioning.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.11" spread="2.50"/>
                    <measurement group_id="O2" value="4.74" spread="2.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.853</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.64</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.41</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quality of Life: Role Functioning</title>
        <description>Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the 5 functional scales measures role functioning.&#xD;
The range of score is 0-100; higher score = better functioning.</description>
        <time_frame>change from pre- to post-intervention (week 12)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention Group</title>
            <description>Prescribed Activity designed to improve patient participation and adherence to prescriptions to increase physical activity and will include: (1) an educational session at enrollment, (2) subject communication via tailored electronic messaging, and (3) a wrist-bound device (FitBit Flex 2).&#xD;
Prescribed Activity: Educational session at enrollment, increase subject communication via tailored electronic messaging, and use of a wrist-bound device (FitBit Flex 2)</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Usual care group will receive standard of care management from their Oncologist.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quality of Life: Role Functioning</title>
          <description>Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the 5 functional scales measures role functioning.&#xD;
The range of score is 0-100; higher score = better functioning.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.09" spread="5.33"/>
                    <measurement group_id="O2" value="-8.95" spread="5.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.022</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>17.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.16</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quality of Life: Emotional Functioning</title>
        <description>Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the 5 functional scales measures emotional functioning.&#xD;
The range of score is 0-100; higher score = better functioning.</description>
        <time_frame>change from pre- to post-intervention (week 12)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention Group</title>
            <description>Prescribed Activity designed to improve patient participation and adherence to prescriptions to increase physical activity and will include: (1) an educational session at enrollment, (2) subject communication via tailored electronic messaging, and (3) a wrist-bound device (FitBit Flex 2).&#xD;
Prescribed Activity: Educational session at enrollment, increase subject communication via tailored electronic messaging, and use of a wrist-bound device (FitBit Flex 2)</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Usual care group will receive standard of care management from their Oncologist.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quality of Life: Emotional Functioning</title>
          <description>Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the 5 functional scales measures emotional functioning.&#xD;
The range of score is 0-100; higher score = better functioning.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.68" spread="2.89"/>
                    <measurement group_id="O2" value="3.11" spread="2.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.911</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.43</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.83</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quality of Life: Fatigue</title>
        <description>Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the symptom scale measures fatigue.&#xD;
The range of score is 0-100; higher score = better functioning.</description>
        <time_frame>change from pre- to post-intervention (week 12)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention Group</title>
            <description>Prescribed Activity designed to improve patient participation and adherence to prescriptions to increase physical activity and will include: (1) an educational session at enrollment, (2) subject communication via tailored electronic messaging, and (3) a wrist-bound device (FitBit Flex 2).&#xD;
Prescribed Activity: Educational session at enrollment, increase subject communication via tailored electronic messaging, and use of a wrist-bound device (FitBit Flex 2)</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Usual care group will receive standard of care management from their Oncologist.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quality of Life: Fatigue</title>
          <description>Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the symptom scale measures fatigue.&#xD;
The range of score is 0-100; higher score = better functioning.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.43" spread="4.85"/>
                    <measurement group_id="O2" value="0.75" spread="4.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.456</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-5.18</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.88</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quality of Life: Cognitive Functioning</title>
        <description>Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the 5 functional scales measures cognitive functioning.&#xD;
The range of score is 0-100; higher score = better functioning.</description>
        <time_frame>change from pre- to post-intervention (week 12)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention Group</title>
            <description>Prescribed Activity designed to improve patient participation and adherence to prescriptions to increase physical activity and will include: (1) an educational session at enrollment, (2) subject communication via tailored electronic messaging, and (3) a wrist-bound device (FitBit Flex 2).&#xD;
Prescribed Activity: Educational session at enrollment, increase subject communication via tailored electronic messaging, and use of a wrist-bound device (FitBit Flex 2)</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Usual care group will receive standard of care management from their Oncologist.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quality of Life: Cognitive Functioning</title>
          <description>Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the 5 functional scales measures cognitive functioning.&#xD;
The range of score is 0-100; higher score = better functioning.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.41" spread="2.26"/>
                    <measurement group_id="O2" value="2.47" spread="2.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.515</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2.05</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.13</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quality of Life: Nausea/Vomiting</title>
        <description>Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the symptom scale measures nausea and vomiting The range of score is 0-100; higher score = better functioning.</description>
        <time_frame>change from pre- to post-intervention (week 12)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention Group</title>
            <description>Prescribed Activity designed to improve patient participation and adherence to prescriptions to increase physical activity and will include: (1) an educational session at enrollment, (2) subject communication via tailored electronic messaging, and (3) a wrist-bound device (FitBit Flex 2).&#xD;
Prescribed Activity: Educational session at enrollment, increase subject communication via tailored electronic messaging, and use of a wrist-bound device (FitBit Flex 2)</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Usual care group will receive standard of care management from their Oncologist.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quality of Life: Nausea/Vomiting</title>
          <description>Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the symptom scale measures nausea and vomiting The range of score is 0-100; higher score = better functioning.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.44" spread="4.18"/>
                    <measurement group_id="O2" value="6.21" spread="4.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.144</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-8.65</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.80</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quality of Life: Pain</title>
        <description>Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the symptom scale measures pain.&#xD;
The range of score is 0-100; higher score = better functioning.</description>
        <time_frame>change from pre- to post-intervention (week 12)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention Group</title>
            <description>Prescribed Activity designed to improve patient participation and adherence to prescriptions to increase physical activity and will include: (1) an educational session at enrollment, (2) subject communication via tailored electronic messaging, and (3) a wrist-bound device (FitBit Flex 2).&#xD;
Prescribed Activity: Educational session at enrollment, increase subject communication via tailored electronic messaging, and use of a wrist-bound device (FitBit Flex 2)</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Usual care group will receive standard of care management from their Oncologist.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quality of Life: Pain</title>
          <description>Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the symptom scale measures pain.&#xD;
The range of score is 0-100; higher score = better functioning.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.67" spread="4.77"/>
                    <measurement group_id="O2" value="1.26" spread="4.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.948</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.41</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.28</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quality of Life: Social Functioning</title>
        <description>Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the 5 functional scales measures social functioning.&#xD;
The range of score is 0-100; higher score = better functioning.</description>
        <time_frame>change from pre- to post-intervention (week 12)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention Group</title>
            <description>Prescribed Activity designed to improve patient participation and adherence to prescriptions to increase physical activity and will include: (1) an educational session at enrollment, (2) subject communication via tailored electronic messaging, and (3) a wrist-bound device (FitBit Flex 2).&#xD;
Prescribed Activity: Educational session at enrollment, increase subject communication via tailored electronic messaging, and use of a wrist-bound device (FitBit Flex 2)</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Usual care group will receive standard of care management from their Oncologist.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quality of Life: Social Functioning</title>
          <description>Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the 5 functional scales measures social functioning.&#xD;
The range of score is 0-100; higher score = better functioning.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.22" spread="5.38"/>
                    <measurement group_id="O2" value="4.40" spread="5.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.254</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-8.62</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.45</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quality of Life: Dyspnea</title>
        <description>Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the scales measure dyspnea.&#xD;
The range of score is 0-100; higher score = higher symptoms burden.</description>
        <time_frame>change from pre- to post-intervention (week 12)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention Group</title>
            <description>Prescribed Activity designed to improve patient participation and adherence to prescriptions to increase physical activity and will include: (1) an educational session at enrollment, (2) subject communication via tailored electronic messaging, and (3) a wrist-bound device (FitBit Flex 2).&#xD;
Prescribed Activity: Educational session at enrollment, increase subject communication via tailored electronic messaging, and use of a wrist-bound device (FitBit Flex 2)</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Usual care group will receive standard of care management from their Oncologist.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quality of Life: Dyspnea</title>
          <description>Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the scales measure dyspnea.&#xD;
The range of score is 0-100; higher score = higher symptoms burden.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.19" spread="4.88"/>
                    <measurement group_id="O2" value="7.12" spread="4.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.051</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-13.31</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.62</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quality of Life: Insomnia</title>
        <description>Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the scales measure insomnia.&#xD;
The range of score is 0-100; higher score = better functioning.</description>
        <time_frame>change from pre- to post-intervention (week 12)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention Group</title>
            <description>Prescribed Activity designed to improve patient participation and adherence to prescriptions to increase physical activity and will include: (1) an educational session at enrollment, (2) subject communication via tailored electronic messaging, and (3) a wrist-bound device (FitBit Flex 2).&#xD;
Prescribed Activity: Educational session at enrollment, increase subject communication via tailored electronic messaging, and use of a wrist-bound device (FitBit Flex 2)</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Usual care group will receive standard of care management from their Oncologist.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quality of Life: Insomnia</title>
          <description>Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the scales measure insomnia.&#xD;
The range of score is 0-100; higher score = better functioning.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.58" spread="6.37"/>
                    <measurement group_id="O2" value="-3.49" spread="6.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.643</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>4.07</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.71</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quality of Life: Appetite Loss</title>
        <description>Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the scales measure appetite loss The range of score is 0-100; higher score = higher symptoms burden.</description>
        <time_frame>change from pre- to post-intervention (week 12)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention Group</title>
            <description>Prescribed Activity designed to improve patient participation and adherence to prescriptions to increase physical activity and will include: (1) an educational session at enrollment, (2) subject communication via tailored electronic messaging, and (3) a wrist-bound device (FitBit Flex 2).&#xD;
Prescribed Activity: Educational session at enrollment, increase subject communication via tailored electronic messaging, and use of a wrist-bound device (FitBit Flex 2)</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Usual care group will receive standard of care management from their Oncologist.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quality of Life: Appetite Loss</title>
          <description>Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the scales measure appetite loss The range of score is 0-100; higher score = higher symptoms burden.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.16" spread="6.60"/>
                    <measurement group_id="O2" value="4.95" spread="6.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.290</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-9.11</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.50</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quality of Life: Constipation</title>
        <description>Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the scales measure constipation.&#xD;
The range of score is 0-100; higher score = higher symptoms burden.</description>
        <time_frame>change from pre- to post-intervention (week 12)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention Group</title>
            <description>Prescribed Activity designed to improve patient participation and adherence to prescriptions to increase physical activity and will include: (1) an educational session at enrollment, (2) subject communication via tailored electronic messaging, and (3) a wrist-bound device (FitBit Flex 2).&#xD;
Prescribed Activity: Educational session at enrollment, increase subject communication via tailored electronic messaging, and use of a wrist-bound device (FitBit Flex 2)</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Usual care group will receive standard of care management from their Oncologist.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quality of Life: Constipation</title>
          <description>Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the scales measure constipation.&#xD;
The range of score is 0-100; higher score = higher symptoms burden.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.21" spread="4.02"/>
                    <measurement group_id="O2" value="-11.19" spread="4.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.077</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>9.99</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.49</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quality of Life: Diarrhea</title>
        <description>Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the scales measure diarrhea.&#xD;
The range of score is 0-100; higher score = higher symptoms burden.</description>
        <time_frame>change from pre- to post-intervention (week 12)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention Group</title>
            <description>Prescribed Activity designed to improve patient participation and adherence to prescriptions to increase physical activity and will include: (1) an educational session at enrollment, (2) subject communication via tailored electronic messaging, and (3) a wrist-bound device (FitBit Flex 2).&#xD;
Prescribed Activity: Educational session at enrollment, increase subject communication via tailored electronic messaging, and use of a wrist-bound device (FitBit Flex 2)</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Usual care group will receive standard of care management from their Oncologist.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quality of Life: Diarrhea</title>
          <description>Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the scales measure diarrhea.&#xD;
The range of score is 0-100; higher score = higher symptoms burden.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="3.32"/>
                    <measurement group_id="O2" value="-5.13" spread="3.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.237</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>5.27</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.38</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quality of Life: Financial Difficulties</title>
        <description>Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the scales measure financial difficulties.&#xD;
The range of score is 0-100; higher score = higher symptoms burden.</description>
        <time_frame>change from pre- to post-intervention (week 12)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention Group</title>
            <description>Prescribed Activity designed to improve patient participation and adherence to prescriptions to increase physical activity and will include: (1) an educational session at enrollment, (2) subject communication via tailored electronic messaging, and (3) a wrist-bound device (FitBit Flex 2).&#xD;
Prescribed Activity: Educational session at enrollment, increase subject communication via tailored electronic messaging, and use of a wrist-bound device (FitBit Flex 2)</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Usual care group will receive standard of care management from their Oncologist.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quality of Life: Financial Difficulties</title>
          <description>Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the scales measure financial difficulties.&#xD;
The range of score is 0-100; higher score = higher symptoms burden.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.56" spread="4.54"/>
                    <measurement group_id="O2" value="5.41" spread="4.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.861</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.15</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.49</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Moderate Aerobic Exercise</title>
        <description>The investigators will use the Physical Activity Questionnaire that measures this outcome in minutes.</description>
        <time_frame>baseline to 12 weeks</time_frame>
        <population>A 12 week outcome was not available for one subject in the control group.</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention Group</title>
            <description>Prescribed Activity designed to improve patient participation and adherence to prescriptions to increase physical activity and will include: (1) an educational session at enrollment, (2) subject communication via tailored electronic messaging, and (3) a wrist-bound device (FitBit Flex 2).&#xD;
Prescribed Activity: Educational session at enrollment, increase subject communication via tailored electronic messaging, and use of a wrist-bound device (FitBit Flex 2)</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Usual care group will receive standard of care management from their Oncologist.</description>
          </group>
        </group_list>
        <measure>
          <title>Moderate Aerobic Exercise</title>
          <description>The investigators will use the Physical Activity Questionnaire that measures this outcome in minutes.</description>
          <population>A 12 week outcome was not available for one subject in the control group.</population>
          <units>Minutes of activity per week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.0" spread="46.4"/>
                    <measurement group_id="O2" value="58.8" spread="55.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128.1" spread="212.4"/>
                    <measurement group_id="O2" value="75.3" spread="111.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vigorous Aerobic Exercise</title>
        <description>The investigators will use the Physical Activity Questionnaire that measures this outcome in minutes.</description>
        <time_frame>baseline to 12 weeks</time_frame>
        <population>A 12 week outcome was not available for one subject in the control group.</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention Group</title>
            <description>Prescribed Activity designed to improve patient participation and adherence to prescriptions to increase physical activity and will include: (1) an educational session at enrollment, (2) subject communication via tailored electronic messaging, and (3) a wrist-bound device (FitBit Flex 2).&#xD;
Prescribed Activity: Educational session at enrollment, increase subject communication via tailored electronic messaging, and use of a wrist-bound device (FitBit Flex 2)</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Usual care group will receive standard of care management from their Oncologist.</description>
          </group>
        </group_list>
        <measure>
          <title>Vigorous Aerobic Exercise</title>
          <description>The investigators will use the Physical Activity Questionnaire that measures this outcome in minutes.</description>
          <population>A 12 week outcome was not available for one subject in the control group.</population>
          <units>Minutes of activity per week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.0"/>
                    <measurement group_id="O2" value="0.0" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.0" spread="82.5"/>
                    <measurement group_id="O2" value="17.4" spread="75.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in C-reactive Protein (CRP)</title>
        <description>The investigators will obtain serum CRP, a marker of inflammation.</description>
        <time_frame>change from pre- to post-intervention (week 12)</time_frame>
        <population>Only n=10 patients provided baseline and follow-up samples; 6 in the intervention group and 4 in the control group.</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention Group</title>
            <description>Prescribed Activity designed to improve patient participation and adherence to prescriptions to increase physical activity and will include: (1) an educational session at enrollment, (2) subject communication via tailored electronic messaging, and (3) a wrist-bound device (FitBit Flex 2).&#xD;
Prescribed Activity: Educational session at enrollment, increase subject communication via tailored electronic messaging, and use of a wrist-bound device (FitBit Flex 2)</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Usual care group will receive standard of care management from their Oncologist.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in C-reactive Protein (CRP)</title>
          <description>The investigators will obtain serum CRP, a marker of inflammation.</description>
          <population>Only n=10 patients provided baseline and follow-up samples; 6 in the intervention group and 4 in the control group.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1,381.34" spread="682.02"/>
                    <measurement group_id="O2" value="-1,242.47" spread="918.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Leptin Level</title>
        <description>The investigators will obtain serum leptin, a marker of glucose control. .</description>
        <time_frame>change from pre- to post-intervention (week 12)</time_frame>
        <population>Only n=10 patients provided baseline and follow-up samples; 6 in the intervention group and 4 in the control group.</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention Group</title>
            <description>Prescribed Activity designed to improve patient participation and adherence to prescriptions to increase physical activity and will include: (1) an educational session at enrollment, (2) subject communication via tailored electronic messaging, and (3) a wrist-bound device (FitBit Flex 2).&#xD;
Prescribed Activity: Educational session at enrollment, increase subject communication via tailored electronic messaging, and use of a wrist-bound device (FitBit Flex 2)</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Usual care group will receive standard of care management from their Oncologist.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Leptin Level</title>
          <description>The investigators will obtain serum leptin, a marker of glucose control. .</description>
          <population>Only n=10 patients provided baseline and follow-up samples; 6 in the intervention group and 4 in the control group.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.34" spread="3.28"/>
                    <measurement group_id="O2" value="-3.31" spread="3.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Insulin Level</title>
        <description>The investigators will obtain serum insulin level, a measure of glucose control.</description>
        <time_frame>change from pre- to post-intervention (week 12)</time_frame>
        <population>Only n=10 patients provided baseline and follow-up samples; 6 in the intervention group and 4 in the control group.</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention Group</title>
            <description>Prescribed Activity designed to improve patient participation and adherence to prescriptions to increase physical activity and will include: (1) an educational session at enrollment, (2) subject communication via tailored electronic messaging, and (3) a wrist-bound device (FitBit Flex 2).&#xD;
Prescribed Activity: Educational session at enrollment, increase subject communication via tailored electronic messaging, and use of a wrist-bound device (FitBit Flex 2)</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Usual care group will receive standard of care management from their Oncologist.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Insulin Level</title>
          <description>The investigators will obtain serum insulin level, a measure of glucose control.</description>
          <population>Only n=10 patients provided baseline and follow-up samples; 6 in the intervention group and 4 in the control group.</population>
          <units>uIU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.08" spread="7.29"/>
                    <measurement group_id="O2" value="8.32" spread="7.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Programmed Death - Ligand</title>
        <description>The investigators will collect soluble PD- L1, a novel cancer marker.</description>
        <time_frame>change from pre- to post-intervention (week 12)</time_frame>
        <population>Only n=10 patients provided baseline and follow-up samples; 6 in the intervention group and 4 in the control group.</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention Group</title>
            <description>Prescribed Activity designed to improve patient participation and adherence to prescriptions to increase physical activity and will include: (1) an educational session at enrollment, (2) subject communication via tailored electronic messaging, and (3) a wrist-bound device (FitBit Flex 2).&#xD;
Prescribed Activity: Educational session at enrollment, increase subject communication via tailored electronic messaging, and use of a wrist-bound device (FitBit Flex 2)</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Usual care group will receive standard of care management from their Oncologist.</description>
          </group>
        </group_list>
        <measure>
          <title>Programmed Death - Ligand</title>
          <description>The investigators will collect soluble PD- L1, a novel cancer marker.</description>
          <population>Only n=10 patients provided baseline and follow-up samples; 6 in the intervention group and 4 in the control group.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.22" spread="8.18"/>
                    <measurement group_id="O2" value="-11.08" spread="11.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Programmed Cell Death (PD-1)</title>
        <description>The investigators will collect soluble PD- 1, a novel cancer marker.</description>
        <time_frame>change from pre- to post-intervention (week 12)</time_frame>
        <population>Only n=10 patients provided baseline and follow-up samples; 6 in the intervention group and 4 in the control group.</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention Group</title>
            <description>Prescribed Activity designed to improve patient participation and adherence to prescriptions to increase physical activity and will include: (1) an educational session at enrollment, (2) subject communication via tailored electronic messaging, and (3) a wrist-bound device (FitBit Flex 2).&#xD;
Prescribed Activity: Educational session at enrollment, increase subject communication via tailored electronic messaging, and use of a wrist-bound device (FitBit Flex 2)</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Usual care group will receive standard of care management from their Oncologist.</description>
          </group>
        </group_list>
        <measure>
          <title>Programmed Cell Death (PD-1)</title>
          <description>The investigators will collect soluble PD- 1, a novel cancer marker.</description>
          <population>Only n=10 patients provided baseline and follow-up samples; 6 in the intervention group and 4 in the control group.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152.76" spread="45.51"/>
                    <measurement group_id="O2" value="-67.03" spread="41.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Twelve weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Intervention Group</title>
          <description>Prescribed Activity designed to improve patient participation and adherence to prescriptions to increase physical activity and will include: (1) an educational session at enrollment, (2) subject communication via tailored electronic messaging, and (3) a wrist-bound device (FitBit Flex 2).&#xD;
Prescribed Activity: Educational session at enrollment, increase subject communication via tailored electronic messaging, and use of a wrist-bound device (FitBit Flex 2)</description>
        </group>
        <group group_id="E2">
          <title>Control Group</title>
          <description>Usual care group will receive standard of care management from their Oncologist.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>hyperthyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ankle pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Brett Bade</name_or_title>
      <organization>Yale University</organization>
      <phone>203 785 6670</phone>
      <email>Brett.bade@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

